Pfizer could have data on how well its Covid-19 vaccine works in kids under age 5 by the end of the year, according to CEO Albert Bourla. "We have a study in children 6 months to 2 years and then ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results